{"url_path":"/sec/gild/8-k/2026-05-20/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/882095/0001104659-26-064518-index.html","accession_number":"0001104659-26-064518","cik":"0000882095","ticker":"GILD","issuer_name":"GILEAD SCIENCES, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/882095/0001104659-26-064518-index.html","primary_entity_key":"0000882095","primary_entity_name":"GILEAD SCIENCES, INC."},"word_count":255,"has_tables":true,"body_markdown":"**Item 9.01.\nFinancial Statements and Exhibits.**\n\n \n\n**(d) Exhibits**\n\n \n\n**Exhibit \nNumber**\n \n**Description**\n\n[1.1](tm2615045d1_ex1-1.htm)\n \n[Underwriting Agreement, dated May 14, 2026, among the Company and Barclays Capital Inc., BofA Securities, Inc. and Citigroup Global Markets Inc., as representatives of the several underwriters listed in Schedule 1 thereto](tm2615045d1_ex1-1.htm)\n\n[4.1](https://www.sec.gov/Archives/edgar/data/882095/000119312511086814/dex41.htm)\n \n[Indenture, dated as of March 30, 2011, between the Company and Computershare Trust Company, National Association, as successor to Wells Fargo Bank, National Association, as Trustee (incorporated by reference from Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed with the Commission on April 1, 2011)](https://www.sec.gov/Archives/edgar/data/882095/000119312511086814/dex41.htm)\n\n[4.2](tm2615045d1_ex4-2.htm)\n \n[Eleventh Supplemental Indenture, dated as of May 20, 2026, between the Company and Computershare Trust Company, National Association, as successor to Wells Fargo Bank, National Association, as Trustee](tm2615045d1_ex4-2.htm)\n\n[4.3](tm2615045d1_ex4-2.htm)\n \n[Form of 2028 Note (included in Exhibit 4.2 above)](tm2615045d1_ex4-2.htm)\n\n[4.4](tm2615045d1_ex4-2.htm)\n \n[Form of 2029 Note (included in Exhibit 4.2 above)](tm2615045d1_ex4-2.htm)\n\n[4.5](tm2615045d1_ex4-2.htm)\n \n[Form of 2031 Note (included in Exhibit 4.2 above)](tm2615045d1_ex4-2.htm)\n\n[4.6](tm2615045d1_ex4-2.htm)\n \n[Form of 2034 Note (included in Exhibit 4.2 above)](tm2615045d1_ex4-2.htm)\n\n[5.1](tm2615045d1_ex5-1.htm)\n \n[Opinion of Sidley Austin LLP regarding the validity of the Notes](tm2615045d1_ex5-1.htm)\n\n[23.1](tm2615045d1_ex5-1.htm)\n \n[Consent of Sidley Austin LLP (included as part of Exhibit 5.1)](tm2615045d1_ex5-1.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n2\n\n \n\n \n\n**SIGNATURE**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \nGILEAD SCIENCES, INC.\n\n \n \n\n \nBy:\n/s/\nAndrew D. Dickinson\n\n \n \nName:\nAndrew D. Dickinson\n\n \n \nTitle:\nExecutive Vice President and Chief Financial\nOfficer\n\n \n\nDated: May 20, 2026\n\n \n\n3"}